A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
The goal of this clinical research study is to learn the best tolerable dose of FT-2102 that can be given alone or in combination with azacitidine or cytarabine to patients with AML or MDS. The safety and effects of the drug will also be studied. This is the first study using FT-2102 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Azacitidine, FT-2102
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: FORMA Therapeutics, Inc.
IRB Review and Approval Date: 06/08/2016
Recruitment Status: Open
Projected Accrual: 430
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: